^
    Evidence Level:
    Sensitive: A1 - Approval

    [ALK positive-Non Small Cell Lung Cancer-brigatinib]

    Source:
    FDA
    Test:

    Vysis ALK Break Apart FISH Probe Kit

    Published date:
    04/28/2017
    Excerpt:
    ALUNBRIG is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
    Evidence Level:
    Sensitive: C3 – Early Trials

    [ALK rearrangement-Lung Non-Squamous Non-Small Cell Cancer-crizotinib]

    Source:
    Sci Rep
    Test:

    Vysis ALK Break Apart FISH Probe Kit

    Title:
    Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
    Published date:
    10/22/2021
    Excerpt:
    We enrolled 95 non-squamous NSCLC patients with known status of EGFR, ALK, ROS1, MET and RET genes and PD-L1 protein expression….In 32 patients with ALK or ROS1 genes rearrangements, 10 patients received crizotinib and 22 patients chemotherapy in the first-line of treatment. The median overall survival was 34 months (95% CI 9.5–34 months) in crizotinib treated patients and 6 months (95% CI 4–15.5 months) in patients who received chemotherapy (HR = 0.266, 95% CI 0.104–0.678, p = 0.0056)...
    DOI:
    https://doi.org/10.1038/s41598-021-00309-3